O'Regan RM - Search Results

1

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).

Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, Girda E, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB. Leal TA, et al. Cancer Med. 2022 Nov;11(21):3969-3981. doi: 10.1002/cam4.4724. Epub 2022 Apr 8. Cancer Med. 2022. PMID: 35396812 Free PMC article. Clinical Trial.

2

Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?

Andic F, Godette K, O'Regan R, Zelnak A, Liu T, Rizzo M, Gabram S, Torres M. Andic F, et al. Cancer. 2011 Dec 15;117(24):5485-92. doi: 10.1002/cncr.26187. Epub 2011 Jun 20. Cancer. 2011. PMID: 21692059 Free article.

3

Role of the androgen receptor in triple-negative breast cancer.

Rampurwala M, Wisinski KB, O'Regan R. Rampurwala M, et al. Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93. Clin Adv Hematol Oncol. 2016. PMID: 27058032 Free PMC article. Review.

4

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. Rampurwala M, et al. Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8. Invest New Drugs. 2017. PMID: 27826831 Free PMC article. Clinical Trial.

5

Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.

Tevaarwerk AJ, Wisinski KB, O'Regan RM. Tevaarwerk AJ, et al. J Oncol Pract. 2016 Nov;12(11):1148-1156. doi: 10.1200/JOP.2016.016865. J Oncol Pract. 2016. PMID: 27858538 Free PMC article. Review.

6

Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.

Sharifi MN, Anandan A, Grogan P, O'Regan RM. Sharifi MN, et al. Cancer. 2020 Aug 1;126(15):3400-3416. doi: 10.1002/cncr.32931. Epub 2020 May 19. Cancer. 2020. PMID: 32426848 Free article. Review.

7

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.

Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Dudek AZ, et al. Breast Cancer Res Treat. 2020 Oct;183(3):617-627. doi: 10.1007/s10549-020-05787-z. Epub 2020 Jul 22. Breast Cancer Res Treat. 2020. PMID: 32696319 Clinical Trial.

8

Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer.

Anandan A, Sharifi M, O'Regan R. Anandan A, et al. Curr Treat Options Oncol. 2020 Aug 15;21(10):84. doi: 10.1007/s11864-020-00788-y. Curr Treat Options Oncol. 2020. PMID: 32803324 Review.

9

Introduction to Special Issue.

Wisinski K, O'Regan R. Wisinski K, et al. Clin Breast Cancer. 2021 Apr;21(2):95. doi: 10.1016/j.clbc.2021.02.007. Clin Breast Cancer. 2021. PMID: 34030860 No abstract available.

10

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel.

Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, Zasadil LM, Molini R, Fitzgerald J, Lager AM, Laffin JJ, Correia-Staudt K, Wisinski KB, Tevaarwerk AJ, O'Regan R, McGregor SM, Fowler AM, Chappell RJ, Bugni TS, Burkard ME, Weaver BA. Scribano CM, et al. Sci Transl Med. 2021 Sep 8;13(610):eabd4811. doi: 10.1126/scitranslmed.abd4811. Epub 2021 Sep 8. Sci Transl Med. 2021. PMID: 34516829 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters